维普期刊资源整合服务平台（V6.5）

30篇 您的检索式：作者名="Weegink"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus–Infected Patients Following TMC435 Monotherapy显示文摘	Oliver Lenz Joep de Bruijne Leen Vijgen Thierry Verbinnen Christine Weegink Herwig Van Marck Ina Vandenbroucke Monika Peeters Kenneth Simmen Greg Fanning Rene Verloes Gaston Picchio Hendrik Reesink	2012	Gastroenterology2012，，5：	1
2	Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study显示文摘	Hendrik W. Reesink Stefan Zeuzem Christine J. Weegink Nicole Forestier Andre van Vliet Jeroen van de Wetering de Rooij Lindsay McNair Susan Purdy Robert Kauffman John Alam Peter L.M. Jansen	2006	Gastroenterology2006，，4：	1
3	Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir显示文摘	Christoph Sarrazin Tara L. Kieffer Doug Bartels Brian Hanzelka Ute Müh Martin Welker Dennis Wincheringer Yi Zhou Hui–May Chu Chao Lin Christine Weegink Henk Reesink Stefan Zeuzem Ann D. Kwong	2007	Gastroenterology2007，，5：	1
4	Initial results of a 14-day study of the hepatitis C virus protease inhibitor VX-950,in combination with peginterferon-α-2a显示文摘	Reesink HW ForestierN Weegink CJ	2006	J Hepatol2006，442，：	1
5	Intrahepatic response markers in chronic hepatitis B patients treated with peginterferonα-2a and adefovir显示文摘	Takkenberg B Terpstra V Zaaijer H Weegink C Dijkgraaf M Jansen P		Journal of Gastroenterology and Hepatology0，，：	1
6	Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C显示文摘	Forestier N Reesink HW Weegink CJ	2007	Hepatology2007，46，3：	1
7	High rate of HBeAg loss and HBeAg seroconversion in chronic hepatitis B patients on combi- nation therapy with peginterferon alfa-2a(Pegasys) and adefovir (He- psera):HBeAg titer predicts HBeAg loss or seroconversion显示文摘	Takkenber B Zaaijer HL Weegink C	2008	Hepatol2008，48，1：	1
8	Rapid de- cline of viral RNA in hepatitis C patients treated with VX- 950: a phase Ib, placebo-controlled, randomized study 显示文摘	Reesink H W Zeuzem S Weegink C J	2006	Gastroenterology2006，131，4：	1
9	Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir显示文摘	Zaaijer HL Takkenberg RB Weegink CJ		0，，03：	1
10	Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir显示文摘	A. de Niet R.B. Takkenberg R. Benayed B. Riley-Gillis C.J. Weegink H.L. Zaaijer M. Koot P.L.M. Jansen M.G.H.M. Beld U. Lopatin H.W. Reesink	2012	Scandinavian Journal of Gastroenterology2012，，4：	1
11	High rate ofHBsAg loss and HBsAg seroconversion in chronic hepatitis Bpatients on combination therapy with pegi nterferon alfa-2a(Peg asys)and adefovir:HBsAg titer predicts HBsAg loss orseroconversion显示文摘	Takkenberg B Zaaijer HL Weegink CJ	2008	Hepatology2008，48，1：	1
12	Colonial History and Contemporary Transmission Shape the Genetic Diversity of Hepatitis C Virus Genotype 2 in Amsterdam显示文摘	Peter V. Markov Thijs J. van de Laar Xiomara V. Thomas Sem J. Aronson Christine J. Weegink Guido E. van den Berk Maria Prins Oliver G. Pybus Janke Schinkel	2012	Journal of Virology2012，，14：	1
13	1242 LONG-TERM FOLLOW-UP OF CHRONIC HEPATITIS C INFECTED PATIENTS TREATED WITH TELAPREVIR: EVALUATION OF PERSISTENCE OF RESISTANT VARIANTS BY ULTRA-DEEP SEQUENCING显示文摘	X.V. Thomas J. de Bruijne T.L. Kieffer J.C. Sullivan S.P. Rebers M. de Vries H.W. Reesink C.J. Weegink R. Molenkamp J. Schinkel	2011	Journal of Hepatology2011，，：	1
14	Development of myasthenia gravis during treatment of chronic hepatitis C with in-terferon-alpha and ribavirin显示文摘	Weegink CJ Chamuleau RA Reesink HW		0，，10：	1
15	Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir显示文摘	Christoph Sarrazin Tara L. Kieffer Doug Bartels Brian Hanzelka Ute Müh Martin Welker Dennis Wincheringer Yi Zhou Hui–May Chu Chao Lin Christine Weegink Henk Reesink Stefan Zeuzem Ann D. Kwong	2007	Gastroenterology2007，，5：	1
16	High rate of HBsAg loss and HBsAg seroconversion in chronic hepatitis B patients on combination 'therapy with peginterferon alfa- 2a(Pegasys) and adefovir(Hepsera): HBsAg titer predicts HBsAgloss or seroconversion显示文摘	Takkenberg B Zaaijer HL Weegink C J	2008	Hepatology2008，48，267：	1
17	Final result of a phaselb, multiple -dose study of VX-950, a hepatitis C virus protease inhibitor显示文摘	REESINK HW ZEUZEM S WEEGINK C J	2005	Hepatology2005，42，1：	1
18	Antiviral ac- tivity of telaprevir (VX-950) and peginterferon alfa -2a in pa- tients with hepatitis C显示文摘	FORESTIER N REESINK HW WEEGINK C J	2007	Hepatology2007，46，3：	1
19	Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study显示文摘	Hendrik W. Reesink Stefan Zeuzem Christine J. Weegink Nicole Forestier Andre van Vliet Jeroen van de Wetering de Rooij Lindsay McNair Susan Purdy Robert Kauffman John Alam Peter L.M. Jansen	2006	Gastroenterology2006，，4：	1
20	New developments in antiviral therapy for chronic hepatitis B 显示文摘	Takkenberg RB Weegink C J Zaaijer HL	2010	Vox Sang2010，98，4：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示